Daré Bioscience closes Regulation A unit sale
Daré Bioscience, Inc. completed a closing of its Regulation A offering, selling 20,000 Investor Units at an offering price of $5.00 per unit.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Daré Bioscience, Inc. completed a closing of its Regulation A offering, selling 20,000 Investor Units at an offering price of $5.00 per unit. Each Investor Unit consists of one share of Series A Convertible Preferred Stock and two Investor Warrants, each warrant exercisable for one share of common stock, for a total of up to 40,000 common shares underlying the warrants. The units were issued under an offering statement on Form 1-A that was most recently qualified by the SEC on April 1, 2026, together with an offering circular dated January 6, 2026 and an offering circular supplement dated March 26, 2026.
8-K Event Classification
Item 3.02 — Unregistered Sales of Equity Securities
1 item
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Key Figures
Maximum Regulation A units: 4,854,000 units
Investor Units sold in closing: 20,000 units
Preferred shares issued: 20,000 shares
+3 more
6 metrics
Maximum Regulation A units
4,854,000 units
Total Investor Units authorized in the Regulation A offering
Investor Units sold in closing
20,000 units
Units issued on completion of the reported closing
Preferred shares issued
20,000 shares
Series A Convertible Preferred Stock included in 20,000 units
Warrants issued
40,000 warrants
Investor Warrants to purchase up to 40,000 common shares
Unit offering price
$5.00 per unit
Offering price for each Investor Unit
Form 1-A qualification date
April 1, 2026
Most recent SEC qualification of the offering statement
Key Terms
Regulation A offering, Series A Convertible Preferred Stock, warrants, offering statement on Form 1-A, +1 more
5 terms
Regulation A offering regulatory
"completed a closing of our previously announced Regulation A offering of up to 4,854,000 units"
A Regulation A offering is a way for smaller companies to sell shares to the public without going through a full, traditional stock market listing. Think of it as a scaled-down public sale that gives everyday investors earlier access to private companies while generally requiring less paperwork and oversight than a full IPO—so it can offer growth opportunities but also carries higher risk and potentially less disclosure than fully regulated public stocks.
Series A Convertible Preferred Stock financial
"each consisting of one share of Series A Convertible Preferred Stock (the “Series A Preferred Stock”)"
Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.
warrants financial
"and two warrants, each to purchase one share of our common stock"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
offering statement on Form 1-A regulatory
"pursuant to our offering statement on Form 1-A (File No. 024-12688), as amended"
offering circular supplement regulatory
"the offering circular dated January 6, 2026, and the offering circular supplement dated March 26, 2026"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Daré Bioscience (DARE) announce in this Form 8-K?
Daré Bioscience reported completing a closing of its Regulation A offering, selling 20,000 Investor Units at $5.00 each. The units include preferred stock and warrants and were issued under a previously qualified Form 1-A offering statement.
How many units did Daré Bioscience (DARE) sell in the Regulation A closing?
Daré Bioscience sold 20,000 Investor Units in this closing. Each unit contains one share of Series A Convertible Preferred Stock and two warrants, giving investors additional potential exposure to Daré’s common stock through future warrant exercises.
What securities are included in Daré Bioscience (DARE) Investor Units?
Each Investor Unit includes one share of Series A Convertible Preferred Stock and two Investor Warrants. Each warrant allows the holder to purchase one share of Daré’s common stock, so 20,000 units carry warrants exercisable for up to 40,000 common shares.
What was the offering price for Daré Bioscience (DARE) Investor Units?
The Investor Units were offered at an offering price of $5.00 per unit. This fixed price applies to each unit, which bundles one preferred share and two common stock purchase warrants into a single investment package for Regulation A investors.
What is the maximum size of Daré Bioscience (DARE) Regulation A offering?
The Regulation A offering covers up to 4,854,000 Investor Units. The reported closing relates to 20,000 units, representing only a portion of the total units that may be offered under the qualified Form 1-A offering statement and related offering circulars.
Under what regulatory framework was Daré Bioscience (DARE) offering qualified?
The offering was qualified under Regulation A through an offering statement on Form 1-A, most recently qualified by the SEC on April 1, 2026. An offering circular dated January 6, 2026 and an offering circular supplement dated March 26, 2026 provide detailed terms.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates